Figure 2.
Rejection of DNAM-1 ligand-expressing RMA tumor cells. Groups of 5 C57BL/6 mice were pretreated with control immunoglobulin or mAbs indicated at days -1, 1, 8, 15, and 22. The mice were inoculated subcutaneously in the back at day 0 with 1 × 105 mock-transduced RMA tumor cells (○) or Cd112- or Cd155-transduced RMA tumor cells (•). Survival data for 5 mice per group are shown.
